Approximately 90% of drug development programs fail. This is most often because the targets of the medicines do not actually cause the disease. This wasteful process leads to high drug development costs, which are then passed on to patients and governments in the form of high prices for medicines. One way to make this drug development process more efficient is to use human genetics to validate the targets of medicines. Doing so increases the probability of success between 2-4-fold.
In the proposed program we will use human genetic methods to be able to identify high-yield targets that can be used to make drug development more efficient. We will develop a machine-learning algorithm that pinpoints the genes that mediate the risk imparted by regions of the genome. Success in this initiative will help the clients of 5 Prime Sciences accelerate their drug development programs, yielding more effective medicines over shorter time scales.
This program will also employ and train highly qualified personnel, attracting them to the growing and unique bio-pharmaceutical ecosystem of Québec and helping to re-establish Québec as a centre for drug development expertise.
Genome Centre: Génome Québec
User:
| Brent | Richards | 5 Prime Sciences |